Vir Biotechnology, Inc. (VIR)
Largest Insider Buys in Sector
VIR Stock Price History Chart
VIR Stock Performance
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of …
Insider Activity of Vir Biotechnology, Inc.
Over the last 12 months, insiders at Vir Biotechnology, Inc. have bought $0 and sold $1.89M worth of Vir Biotechnology, Inc. stock.
On average, over the past 5 years, insiders at Vir Biotechnology, Inc. have bought $123,670 and sold $55.74M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $56,816 was made by Sigal Charles Elliott (director) on 2023‑03‑01.
List of Insider Buy and Sell Transactions, Vir Biotechnology, Inc.
| 2024-11-06 | Sale | EVP and General Counsel | 4,397 0.0032% | $10.11 | $44,454 | -9.05% | ||
| 2024-11-05 | Sale | EVP and General Counsel | 2,347 0.0017% | $9.47 | $22,225 | +7.13% | ||
| 2024-11-01 | Sale | EVP and General Counsel | 1,403 0.0008% | $7.20 | $10,107 | +1.19% | ||
| 2024-09-09 | Sale | director | 12,190 0.0089% | $7.80 | $95,032 | -1.02% | ||
| 2024-06-11 | Sale | director | 4,000 0.003% | $10.95 | $43,789 | -21.78% | ||
| 2024-04-03 | Sale | Chief Executive Officer | 72,995 0.0528% | $9.46 | $690,365 | -9.29% | ||
| 2024-04-01 | Sale | EVP & Chief Technology Officer | 2,711 0.002% | $10.05 | $27,251 | -12.94% | ||
| 2024-03-27 | Sale | EVP & Chief Financial Officer | 6,008 0.0044% | $9.89 | $59,404 | -11.39% | ||
| 2024-02-26 | Sale | director | 17,722 0.0129% | $11.65 | $206,522 | -22.44% | ||
| 2024-02-22 | Sale | EVP & Chief Medical Officer | 14,568 0.0106% | $10.05 | $146,344 | -10.24% | ||
| 2024-02-22 | Sale | EVP & Chief Technology Officer | 12,296 0.0089% | $10.05 | $123,521 | -10.24% | ||
| 2024-02-22 | Sale | director | 10,028 0.0073% | $10.05 | $100,737 | -10.24% | ||
| 2024-02-20 | Sale | director | 16,872 0.0126% | $10.22 | $172,385 | -9.53% | ||
| 2024-02-16 | Sale | EVP & Chief Medical Officer | 3,321 0.0025% | $10.24 | $34,006 | -9.66% | ||
| 2024-02-16 | Sale | director | 10,878 0.0081% | $10.24 | $111,386 | -9.66% | ||
| 2023-06-30 | Sale | 10 percent owner | 700 0.0005% | $25.11 | $17,577 | -59.52% | ||
| 2023-06-30 | Sale | director | 18,000 0.0136% | $24.66 | $443,916 | -59.52% | ||
| 2023-06-29 | Sale | 10 percent owner | 89,942 0.0679% | $25.18 | $2.26M | -60.15% | ||
| 2023-06-28 | Sale | 10 percent owner | 7,010 0.0053% | $25.10 | $175,922 | -59.93% | ||
| 2023-06-20 | Sale | 10 percent owner | 9,902 0.0075% | $25.18 | $249,302 | -59.67% |
Insider Historical Profitability
| HANLY ANN M. | EVP & Chief Technology Officer | 132069 0.0959% | $6.95 | 1 | 5 | <0.0001% |
| SVF Endurance (Cayman) Ltd | 10 percent owner | 16684041 12.1145% | $6.95 | 1 | 80 | +115.34% |
| Alaska Permanent Fund Corp | 10 percent owner | 5555556 4.034% | $6.95 | 1 | 0 | +115.34% |
| Temasek Holdings (Private) Ltd | 10 percent owner | 5499999 3.9936% | $6.95 | 1 | 0 | +115.34% |
| Abu Dhabi Investment Authority | 3666666 2.6624% | $6.95 | 1 | 0 | +115.34% |
Institutional Investor Ownership
| SoftBank Investment Advisers | $169.01M | 12.26 | 16.68M | 0% | +$0 | 1.67 | |
| BlackRock | $167.79M | 12.17 | 16.56M | -1.78% | -$3.05M | <0.01 | |
| The Vanguard Group | $125.36M | 9.1 | 12.38M | +0.64% | +$792,328.08 | <0.01 | |
| State Street | $71.6M | 5.2 | 7.07M | +2.25% | +$1.58M | <0.01 | |
| Baillie Gifford Co | $39.98M | 2.9 | 3.95M | -0.47% | -$187,242.92 | 0.03 |